Metsera touts long-acting GLP-1 drug; Novartis strikes an AI deal
网页1 天前 · Obesity drug startup Metsera on Tuesday reported its first clinical data since launching in April with $290 million in venture funding. The data come from a Phase 1 trial of a drug, MET-097, that ...
Metsera Reports Highly Competitive Results from Ongoing
网页1 天前 · NEW YORK--(BUSINESS WIRE)--Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced positive topline results from the Phase 1 clinical trial of MET-097, an ultra long-acting injectable, fully-biased GLP-1 receptor agonist.
Metsera GLP-1 data slice reveals 7.5% weight loss at 36 days
网页1 天前 · Metsera links long-acting GLP-1 shot to 7.5% weight loss at 36 days, mulls monthly dosing. Recently debuted Metsera is unfolding some phase 1 data for its GLP-1 receptor agonist, revealing a 7.5% ...
Metsera Reports Highly Competitive Results from Ongoing Trial of …
网页1 天前 · Results include 7.5% reduction in body weight from baseline at day 36 Weight loss continued to at least 4 weeks after last dose administered MET-097, incorporating Metsera’s HALO™ platform ...
Metsera Reports Highly Competitive Results from Ongoing Trial of …
网页1 天前 · Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced positive topline results from the Phase 1 clinical trial of MET-097, an ultra long-acting injectable, fully-biased GLP-1 receptor agonist.
New Weight Loss Biotech Metsera Stuns with 7.5% Weight Loss
网页1 天前 · Metsera said this was consistent with or better than marketed products, which include Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, and other GLP-1/GIP compounds in clinical development. Cumulative weight loss in this dose group was 8.1% at day 57, four weeks after the last dose, which shows a durable effect from the therapy, Metsera said.
Readout Newsletter: Metsera, Novo Nordisk, Bluebird Bio updates
网页1 天前 · Metsera’s GLP-1 drug has potential for monthly dosing. This morning, Metsera, a new obesity biotech, reported that its GLP-1 drug led to substantial and durable weight loss in a Phase 1 study ...
News - Metsera
网页GLP-1 portfolio: led by an injectable, fully-biased GLP-1 receptor agonist in Phase 1 clinical trials with a potential class-leading duration of effect
GLP-1 start-up Metsera launches with $290 million
网页2024年4月18日 · Metsera is advancing a suite of peptide and peptide-antibody conjugate drugs for weight loss and other indications, all based on GLP-1 agonists.
Weight-loss drug developer Metsera raises $290 million in funding
网页2024年4月18日 · Metsera, founded in 2022 by venture capital firm ARCH Venture and investment firm Population Health Partners, is developing injectable and oral drugs to treat obesity, based on the GLP-1...
- 某些结果已被删除